However, Hjortebjerg et al. [22] showed that the marked increase in PAPP-A in heparin administration did not increase CT-IGFBP-4, furthermore, encouraging its potentiality as a superior risk marker in acute coronary syndrome (ACS). The gene discussed is PAPPA; the disease is acute coronary syndrome.